Mid-cap Health Care company Exelixis has logged a -4.2% change today on a trading volume of 2,898,141. The average volume for the stock is 2,399,137.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. Based in Alameda, United States the company has 1,223 full time employees and a market cap of $6,413,785,088.
The company is now trading -21.8% away from its average analyst target price of $25.76 per share. The 17 analysts following the stock have set target prices ranging from $18.0 to $32.0, and on average give Exelixis a rating of buy.
Over the last 52 weeks, EXEL stock has risen 24.0%, which amounts to a 7.0% difference compared to the S&P 500. The stock's 52 week high is $22.8 whereas its 52 week low is $15.32 per share. With its net margins declining an average -27.0% over the last 5 years, Exelixis may not have a strong enough profitability trend to support its stock price.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) |
|---|---|---|---|
| 2023 | 1,714,291 | 209,279 | 12 |
| 2022 | 1,611,062 | 234,352 | 15 |
| 2021 | 1,434,970 | 231,063 | 16 |
| 2020 | 967,775 | 321,012 | 33 |
| 2019 | nan | nan | |
| 2018 | 853,826 | 690,070 | 81 |
